Ophthalmologists Favor Genentech’s Vabysmo and Regeneron’s Eylea HD for Diabetic Macular Edema Treatment Despite Payer Constraints June 24, 2024
Novartis’ Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment June 13, 2024
Rheumatologists’ Aggressive Approach to SLE Treatment Targets Specific Patient Types with Biologics June 13, 2024